Ocular Therapeutix Announces Pricing of Underwritten Common Stock Offering

BEDFORD, Mass.—Ocular Therapeutix, Inc., (Nasdaq: OCUL) a leading, integrated biopharmaceutical company in the retina space, has announced the pricing of an underwritten offering of 37,909,018 shares of its common stock. At an offering price of $12.53 per share, expected gross proceeds from the transaction are approximately $475.0 million, prior to the deduction of underwriting discounts, commissions, and other offering expenses. According to the announcement, all of the shares in the offering are to be sold by the company, and the offering is expected to close on or about today, October 1, subject to the satisfaction of customary closing conditions.